Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
KHAN Technology Transfer Fund I is an early-stage life sciences venture fund based in Europe, founded to create value through cooperative drug development partnerships with academic innovators. The fund focuses on translating academic projects into commercially viable assets, particularly in the area of first-in-class therapies for markets with high unmet medical needs.
Currently, KHAN Technology Transfer Fund I manages an AUM of €70 million and has funded over 50 scientific assets and more than 10 startups. The firm operates primarily in the biotech and healthcare sectors, emphasizing innovative technology transfer in drug discovery. Their collaborative approach with academic institutions, including access to the Max Planck Society, enhances their ability to bridge the gap between academia and industry.
KHAN Technology Transfer Fund I invests in early-stage life sciences projects, specifically targeting first-in-class therapeutics. The fund emphasizes innovative technology transfer in drug discovery and aims to address the gap between academia and industry. It provides flexible funding and support to structure projects and build companies, without requiring fully validated assets or complete teams at the outset.
The fund focuses on funding stages from pre-seed to Series A, primarily in the biotech and healthcare sectors. Their investment strategy includes collaboration with academic institutions to facilitate the development of drug assets, ensuring that they can support projects that may not yet have fully validated assets.
KHAN Technology Transfer Fund I has funded over 50 scientific assets and more than 10 startups. While specific names and descriptions of portfolio companies are not provided, the fund's focus on early-stage life sciences projects indicates a commitment to supporting innovative drug development initiatives.
The portfolio reflects the fund's emphasis on first-in-class therapeutics, targeting markets with high unmet medical needs. This strategic focus positions KHAN Technology Transfer Fund I as a key player in the biotech and healthcare sectors.
Michael Hamacher - Managing Partner/CFO. Michael has extensive experience in venture capital and finance, focusing on life sciences investments.
Bert Klebl - Managing Partner/CEO. Bert has a strong background in drug development and has led numerous successful investments in the biotech sector.
Peter Nussbaumer - Managing Partner. Peter brings expertise in technology transfer and has a history of working with academic institutions.
Johannes Bange - Partner. Johannes specializes in early-stage investments in life sciences and has a keen interest in innovative therapeutics.
Markus Peters - Partner (KHAN-II). Markus has a background in venture capital and focuses on supporting startups in the healthcare sector.
Michael Krebs - Managing Partner (KHAN-I). Michael has significant experience in managing venture funds and supporting biotech startups.
Jan Adams - Partner (KHAN-II). Jan has expertise in life sciences and is involved in evaluating early-stage investment opportunities.
To pitch KHAN Technology Transfer Fund I, founders should visit their website at khan-i.de. It is advisable to include a clear outline of the project, its potential impact, and any collaborations with academic institutions in the pitch deck.
What are the investment criteria for KHAN Technology Transfer Fund I?
The fund invests in early-stage life sciences projects, particularly those targeting first-in-class therapeutics. They focus on pre-seed to Series A funding stages and prioritize projects that address high unmet medical needs.
How can I pitch to KHAN Technology Transfer Fund I?
Founders can submit pitches through their website at khan-i.de. The fund encourages innovative drug development projects and values collaboration with academic institutions.
What makes KHAN Technology Transfer Fund I different from other investors?
KHAN Technology Transfer Fund I emphasizes cooperative drug development partnerships with academic innovators, providing flexible funding without requiring fully validated assets or complete teams at the outset.
What is the geographic focus of KHAN Technology Transfer Fund I?
The fund primarily operates in Europe, collaborating with various academic institutions to facilitate drug asset development.
What type of support does KHAN Technology Transfer Fund I provide to portfolio companies?
The fund offers flexible funding and support to structure projects and build companies, focusing on innovative technology transfer in drug discovery.
What is the typical check size for investments?
While specific check sizes are not disclosed, KHAN Technology Transfer Fund I focuses on early-stage funding, which typically involves smaller investments compared to later-stage rounds.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.